Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $544.53 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Altimmune Inc had its IPO on 2005-10-06 under the ticker symbol ALT.
The company operates in the Healthcare sector and Biotechnology industry. Altimmune Inc has a staff strength of 52 employees.
Shares of Altimmune Inc opened at $4.23 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $4.19 - $4.43, and closed at $4.32.
This is a +3.1% increase from the previous day's closing price.
A total volume of 3,666,821 shares were traded at the close of the day’s session.
In the last one week, shares of Altimmune Inc have slipped by -60.58%.
Altimmune Inc's Key Ratios
Altimmune Inc has a market cap of $544.53 million, indicating a price to book ratio of 2.5847 and a price to sales ratio of 162.9822.
In the last 12-months Altimmune Inc’s revenue was $-68000 with a gross profit of $-70520000 and an EBITDA of $-87612664. The EBITDA ratio measures Altimmune Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Altimmune Inc’s operating margin was 128902.94% while its return on assets stood at -25.73% with a return of equity of -44.07%.
In Q4, Altimmune Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.
Altimmune Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Altimmune Inc’s profitability.
Altimmune Inc stock is trading at a EV to sales ratio of 99.2173 and a EV to EBITDA ratio of -3.7915. Its price to sales ratio in the trailing 12-months stood at 162.9822.
Altimmune Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $206.93 million
- Total Liabilities
- $17.05 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Altimmune Inc ended 2023 with $206.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $206.93 million while shareholder equity stood at $185.29 million.
Altimmune Inc ended 2023 with $0 in deferred long-term liabilities, $17.05 million in other current liabilities, in common stock, $-377884000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $111.10 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Altimmune Inc’s total current assets stands at $192.81 million while long-term investments were $0 and short-term investments were $73.78 million. Its net receivables were $173000.00 compared to accounts payable of $4.80 million and inventory worth $0.
In 2023, Altimmune Inc's operating cash flow was $0 while its capital expenditure stood at $38000.
Comparatively, Altimmune Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Altimmune Inc stock is currently trading at $4.32 per share. It touched a 52-week high of $23.49 and a 52-week low of $23.49. Analysts tracking the stock have a 12-month average target price of $29.38.
Its 50-day moving average was $12.21 and 200-day moving average was $12.6 The short ratio stood at 4.78 indicating a short percent outstanding of 0%.
Around 81.4% of the company’s stock are held by insiders while 9414.2% are held by institutions.
Frequently Asked Questions About Altimmune Inc
Similar Industry Stocks (Biotechnology)
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.